Haematology
Von Willebrand disease – increasing awareness and access to vital care
November 4, 2025Medical Communications, Research and Development European Medicines Association, Haematology, Takeda, Von Willebrand Disease, clinical trials, disease awareness
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about Von Willebrand disease, its causes …
Roche candidate shows early promise for treating haemophilia A
June 25, 2025Research and Development Chugai, Haematology, Roche, clinical trial, haemophilia a, prophylactic therapy
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational bispecific antibody for haemophilia A. …
Novo Nordisk presents promising findings for haemophilia treatment
June 23, 2025Medical Communications, Research and Development Haematology, International Society on Thrombosis and Haemostasis Congres, Novo Nordisk, clinical trial data, haemophilia, market approval
Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment from emicizumab without a need …
First UK patient treated with CSL Behring’s gene therapy for Haemophilia B
June 20, 2025Research and Development CSL Behring, Haematology, NHS England, cell therapy, gene therapy, haemophilia B, prophylactic infusions
CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene dezaparvovec) through the NHS, marking …
PL BioScience and DewCell sign LOI to Jointly Develop Artificial Human Platelets for Scalable, Animal-Free Cell Culture Media
May 23, 2025Research and Development Animal-Free, Artificial Human Platelets, Corporate, DewCell, Haematology, Human Platelet Lysate, Letter of Intent, Oncology, PL Bioscience
PL BioScience and DewCell Biotherapeutics have signed a Letter of Intent (LOI) for the development and supply of artificial human …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
May 22, 2025Market Access, Research and Development Haematology, Hympavzi, NHS, NICE, Pfizer, haemophilia B, marstacimab
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final …
Novartis releases new data across oncology and haematology pipelines
May 21, 2025Research and Development ASCO, EHA, Haematology, Novartis, Oncology, oncology
Novartis has announced it will present new data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking …
Terumo’s plasma donation system adopted by Join Parachute to expand access to lifesaving therapies
May 13, 2025Biotech/start-up, Sales and Marketing Haematology, Join Parachute, Pharmacy, Terumo Blood and Cell Technologies (Terumo BCT), biotech, plasma donation
US Biotech company, Terumo Blood and Cell Technologies (Terumo BCT), has announced that Join Parachute will adopt its Rika Plasma …
Sobi and Sanofi’s Foundation S renew partnership with World Federation of Hemophilia
April 28, 2025Pharmacy sales & educational programmes, Sales and Marketing Haematology, Sanofi, World Federation of Hemophilia, bleeding disorder, sobi
Sobi and Sanofi, through its organisation Foundation S, have extended their partnership with the World Federation of Hemophilia (WFH) Humanitarian …
First cohort dosed with potential treatment for Von Willebrand disease
April 11, 2025Research and Development Haematology, Hemab Therapeutics, Richmond Pharma, Von Willebrand Disease, bleeding disorder
UK-based clinical trials company, Richmond Pharmacology, has completed the first stage of Velora Pioneer, a phase 1/2 clinical trial investigating …
Qfitlia approved by FDA to treat haemophilia A or B
March 31, 2025Research and Development FDA, Haematology, Sanofi, haemophilia, pharma
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran) as the first therapy in the US to treat …
Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine
August 9, 2024Research and Development Haematology, Janssen, New England Journal of Medicine, Obstetrics & Gynaecology, foetus, newborn, women's health
Johnson & Johnson company Janssen has announced that the results from its phase 2 trial into nipocalimab have been published …
AstraZeneca’s AMPLIFY trial interim analysis demonstrates positive results for Calquence plus venetoclax
July 30, 2024Research and Development AstraZeneca, Haematology, chronic lymphocytic leukaemia, haematology, trial analysis
AstraZeneca has announced positive high-level results from an interim analysis for its AMPLIFY phase 3 trial, combining AstraZeneca’s Calquence (acalabrutinib) …
Results from Sanofi’s ALTUVIIIO XTEND-Kids phase 3 trial published in NEJM
July 22, 2024Research and Development Altuviiio, Haematology, Sanofi, haemophilia
Sanofi has announced that full results from the XTEND-Kids phase 3 study were published in The New England Journal of …
EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment
June 19, 2024Medical Communications Altuvoct, EC, EMA, Haematology, haemophilia a, sobi
Sobi has announced that the European Commission (EC) has granted marketing authorisation for Altuvoct (efanesoctocog alfa) for the treatment and …
